We've reached a point where we can extend a mouse’s life by 30% through tweaks to pathways like mTOR and senolytics, yet we’re still seeing a near-total failure in translating those results to human clinical reality. The problem’s simple: a lab mouse isn't "old" in any sense we’d recognize. It’s a metabolic outlier living in a protected vacuum. We’re essentially funding the preservation of a domesticated bug instead of learning how to repair a human machine.

In my work on tenocyte life history, the temporal mismatch is the elephant in the room. A mouse lives two years. Its collagen matrix—the very scaffolding of its existence—barely has time to experience significant non-enzymatic glycation (NEG) or the deep accumulation of cross-links that characterize the human long-game. A human heart valve or tendon has to survive 80 years of cyclic loading and mechanical fatigue. A mouse "aging" in a plastic box with unlimited chow isn't facing structural exhaustion; it's just experiencing a bit of proteostatic drift.

By funneling the vast majority of our capital into these metabolic sprinters, we’re ignoring the mechanical debt that defines human longevity. It’s like trying to keep a skyscraper standing by studying why a tent collapses in a light breeze. Most interventions that work in mice are just correcting the artifact phenotypes of inbreeding and captivity—metabolic glitches that don't exist in the wild, let alone in a long-lived primate.

We need a radical shift in how we prioritize funding. We’ve got to pivot away from the "dozen-mouse cure" and toward comparative mechanobiology and long-baseline human matrix studies. I don't understand why we aren't funding massive, multi-decade proteomics on the Greenland shark or the Bowhead whale. These organisms solved the problem of matrix maintenance over centuries, yet we’re obsessed with a rodent that hasn't even mastered the art of staying alive for a thousand days.

It’s definitely easier to get a clean p-value on an inbred strain that’s been pre-selected to respond to our drugs. But until we move beyond this laboratory simulacrum, we aren't studying aging; we’re just debugging an artificial software error we created in the 20th century.

I’m looking for collaborators who are ready to stop chasing mouse data and start looking at the bio-temporal endurance of the human scaffold. We need to fund the hard stuff—the slow stuff—or we’ll just keep "curing" aging in mice until the sun goes out.